Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Stein

Showing results (11-20 of 100) with videos related to

Pageof 10
Sort By:
Pharmacoeconomics|May 18, 2005
Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemiaKim Dalziel, Ali Round, Ruth Garside, et al.
Pharmacoeconomics|October 10, 2013
Methods to elicit probability distributions from experts: a systematic review of reported practice in health technology assessmentBogdan Grigore, Jaime Peters, Christopher Hyde, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2006
Putting the 'Q' in quality adjusted life years (QALYs) for advanced ovarian cancer - An approach using data clustering methods and the internetKen Stein, Catherine Sugar, Galina Velikova, et al.
BMC Medical Informatics and Decision Making|September 6, 2017
EXPLICIT: a feasibility study of remote expert elicitation in health technology assessmentBogdan Grigore, Jaime Peters, Christopher Hyde, et al.
BJU International|September 3, 2011
Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancerLanting Lu, Jaime Peters, Chris Roome, et al.
The Lancet. Oncology|May 21, 2011
NICE guidance on azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia, and acute myeloid leukaemiaWhitney Miller, Joanne Holden, Elisabeth George, et al.
International Journal of Technology Assessment in Health Care|September 18, 2012
Cost-effectiveness of alemtuzumab for T-cell prolymphocytic leukemiaLanting Lu, Jaime Peters, Chris Roome, et al.
Stroke|August 17, 2012
Maximizing the population benefit from thrombolysis in acute ischemic stroke: a modeling study of in-hospital delaysThomas Monks, Martin Pitt, Ken Stein, et al.
International Journal of Technology Assessment in Health Care|October 23, 2009
Using information graphics in health technology assessment: toward a structured approachMartin Pitt, Will Stahl-Timmins, Rob Anderson, et al.
BMJ (Clinical Research Ed.)|May 6, 2014
Hyperacute stroke care and NHS England's business planThomas Monks, Martin Pitt, Ken Stein, et al.
Pageof 10

Showing results (11-20 of 100) with videos related to

Sort By:
Pageof 10
Pharmacoeconomics|May 18, 2005
Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemiaKim Dalziel, Ali Round, Ruth Garside, et al.
Pharmacoeconomics|October 10, 2013
Methods to elicit probability distributions from experts: a systematic review of reported practice in health technology assessmentBogdan Grigore, Jaime Peters, Christopher Hyde, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2006
Putting the 'Q' in quality adjusted life years (QALYs) for advanced ovarian cancer - An approach using data clustering methods and the internetKen Stein, Catherine Sugar, Galina Velikova, et al.
BMC Medical Informatics and Decision Making|September 6, 2017
EXPLICIT: a feasibility study of remote expert elicitation in health technology assessmentBogdan Grigore, Jaime Peters, Christopher Hyde, et al.
BJU International|September 3, 2011
Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancerLanting Lu, Jaime Peters, Chris Roome, et al.
The Lancet. Oncology|May 21, 2011
NICE guidance on azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia, and acute myeloid leukaemiaWhitney Miller, Joanne Holden, Elisabeth George, et al.
International Journal of Technology Assessment in Health Care|September 18, 2012
Cost-effectiveness of alemtuzumab for T-cell prolymphocytic leukemiaLanting Lu, Jaime Peters, Chris Roome, et al.
Stroke|August 17, 2012
Maximizing the population benefit from thrombolysis in acute ischemic stroke: a modeling study of in-hospital delaysThomas Monks, Martin Pitt, Ken Stein, et al.
International Journal of Technology Assessment in Health Care|October 23, 2009
Using information graphics in health technology assessment: toward a structured approachMartin Pitt, Will Stahl-Timmins, Rob Anderson, et al.
BMJ (Clinical Research Ed.)|May 6, 2014
Hyperacute stroke care and NHS England's business planThomas Monks, Martin Pitt, Ken Stein, et al.
Pageof 10